E Sh-tdown To End

*Colombian Ecopetrol is up 5% today hitting $18.2 a new 12-mo high for EC.

*Israel offshore oil developer Delek Group is up 5.4% today in part because Negev residents are objecting to windmills to generate electricity cheaply in the region. DGRLY offers classic oil and gas. It also will gain from the sale of the Tel Aviv Stock Exchange.

Drugs and Health

*Teva allegedly is worth $30/sh according to Jana Partners which has taken a large but unknown stake in the Israel generic drug firm. This has boosted TEVA stock which earlier fell 3% over its annoulcement that its asthma injection drug reslizsumab (Cinqair) failed phase 3 trials preventing attacks in people with high blood eosinophils. However the intravenous formulation works. This is good news for GlaxoSmithKline of the UK.

*For GSK, its supplemental new drug application for Trelegy Ellipta is under FDA review, now that the US gummint is back in business. GSK reports Feb. 7 at 9 am EST.

*Sanofi's (SNY) purchase of US hemophilia specialist Bioverativ which was spun out by Biogen for $11.6 bn is a shot across the bow for Danish Novo Nordisk which developed its own hemophilia drug. SNY already produces a RNA interference leukemia drug called fitusiran. This boosted the price of Biotest, a German firm which has to sell its Swedish Biovitrum leukemia arm to be taken over by a Chinese firm. NVO is in an M&A tangle already to buy Dutch Ablynx which also does blood disease drugs but it could move on nearby Sweden.Bioverativ is working in RNA interference to treat leukemia, which is a genetic disease.

*Also affected is Swiss Roche's hemophilia drug Hemlibra which uses weekly injections of antibodies to block bleeding episodes in patients whose disease developed resistance to other treatments like transfusions. Its Tecentriq treatment for lung cancer won Japanese approval.

*Worst hit by the SNY deal will be Irish Shire which bought Baxalta to enter the leukemia fray. Its factor durg for hemophilia, Adynovi, just got EU okay last week. Columbine Capital cut SHPG to unfavorable from neutral today.

*Mazor Robotics is up 8.7% today on no new news, although it did tell the world earlier this month that it got 27 new orders for its robotic surgical assistance systems in Q4, 24 Mazor X and 3 Renaissance, and it predicted Q4 sales would be $19 mn and full year sales for 2017 $65 mn. MZOR is Israeli.

View single page >> |

Disclosure: None.

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.


Leave a comment to automatically be entered into our contest to win a free Echo Show.